en · de · es · fr · pt
cardarine-notes.peptides1126.com › Guide › Mechanism And Research Context — Deep Dive

Mechanism And Research Context — Deep Dive

By Editorial Desk · published 2026-06-06 · last reviewed 2026-07-03 · Guide

A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-07-03. Anything still debated is marked as such rather than presented as settled.

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Cardarine at a glance

PropertyValueNotes
SolubilitySoluble in dimethyl sulfoxide and some organic solvents; practically insoluble in waterSolvent choice affects laboratory handling
Typical storage-20 °C, desiccated, protected from lightCommon condition for research samples
Analytical methodLiquid chromatography–tandem mass spectrometry (LC-MS/MS)Used for identification and quantification in biological or product samples
Common synonymsGW501516, GW-501516, GSK-516, EndurobolNames found in research and anti-doping literature
Regulatory statusUnapproved therapeutic; prohibited in competitive sportStatus can vary by country and context

Detection and Regulatory Landscape

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Related pages on this site

Preclinical Findings and Safety Signals

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Identity and Pharmacological Mechanism

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Detection, Stability, and Quality

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Notes from published material

=== August === 2 August – The BBC reports that Labour has shelved £1.3bn of funding promised by the Conservatives for tech and artificial intelligence (AI) projects, including an exascale supercomputer at Edinburgh University. 6 August – The UK government begins the process of drawing up legislation to abolish the Strikes (Minimum Service Levels) Act 2023, which required striking workers such as teachers, firefighters and railway staff to provide a minimum level of service. The Senedd is recalled to choose a new First Minister of Wales, with Eluned Morgan nominated to become the first woman to hold the post. 7 August – Ofcom have received more than 8,200 complaints about two interviews during the 5 August edition of Good Morning Britain – the first involving presenter Ed Balls who spoke to his wife, Home Secretary Yvette Cooper, and the second involving an interview Balls and Kate Garraway did with Labour MP Zarah Sultana. Mark Drakeford, Wales's former first minister, returns to government after he is appointed health secretary by Eluned Morgan. 8 August – The Northern Ireland Assembly is recalled to discuss the 2024 United Kingdom riots. Nominations open for the 2024 Scottish Conservatives leadership election. Ricky Jones, a Labour councillor in Dartford, is suspended by his party and arrested over comments made at an anti-racism rally the previous day in which he suggested far-right protestors who took part in the 2024 UK riots should have their throats cut.

Weight regain is common upon discontinuation of weight loss medications, and long-term therapy may sometimes be required for sustained weight loss. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year. People return to their previous weight within a year and a half after stopping anti-obesity medications. Media related to Anti-obesity drugs at Wikimedia Commons Prescription Medications to Treat Overweight & Obesity US National Institute of Diabetes and Digestive and Kidney Diseases

The patches are also included in the game version sold on the GOG.com distribution service. Boyarsky voiced his support for unofficial patches, saying, "they've found the stuff that we hoped people would find about the game, in terms of the different paths you can take and how it played differently for every class." Boyarsky said that while he would have preferred that the game was more successful at launch, that people were still playing and modifying it made Troika's efforts feel more "worthwhile". Schaffer released a remastered version of his score through Milan Records in October 2019, including eight previously unreleased tracks. The score could be purchased on compact disc, digital download, and a blood-red vinyl record version with a marbled, black smoke effect housed in a custom sleeve.

Sources: en.wikipedia.org

Further detail

== Health claims == By the early 2010s, "bone broth" had become a popular health food trend, due to the resurgence in popularity of dietary fat over sugar, and interest in "functional foods" to which "culinary medicinals" such as turmeric and ginger could be added. Bone broth bars, bone broth home delivery services, bone broth carts, and bone broth freezer packs grew in popularity in the United States. The fad was heightened by the 2014 book Nourishing Broth, in which authors Sally Fallon Morell and Kaayla T. Daniel claim that the broth's nutrient density has a variety of health effects. There is no scientific evidence to support many of the claims made for bone broth.

Dexamethasone is used to treat many inflammatory and autoimmune disorders, such as rheumatoid arthritis and bronchospasm. Idiopathic thrombocytopenic purpura, a decrease in numbers of platelets due to an immune problem, responds to 40 mg daily for four days; it may be administered in 14-day cycles. It is unclear whether dexamethasone in this condition is significantly better than other glucocorticoids. It is also given in small amounts before and/or after some forms of dental surgery, such as the extraction of the wisdom teeth, an operation that often causes puffy, swollen cheeks. Dexamethasone is commonly given as a treatment for croup in children. A single dose can reduce the swelling of the airway to improve breathing and reduce discomfort. Dexamethasone is sometimes injected into the heel when treating plantar fasciitis or heel pain, sometimes in conjunction with triamcinolone acetonide. There is no evidence that this treatment helps in the long term, however, dexamethasone may provide short-term pain relief. It may be useful to counteract allergic anaphylactic shock, however this is not usually recommended by clinical guidelines. It is present in certain eye drops – particularly after eye surgery – and as a nasal spray, and certain ear drops (can be combined with an antibiotic and an antifungal). Dexamethasone intravitreal steroid implants have been approved by the US Food and Drug Administration (FDA) to treat ocular conditions such as diabetic macular edema, central retinal vein occlusion, and uveitis.

(1978), federal judge of the United States District Court for the District of New Jersey Rolando Acosta (1979), associate justice of the Appellate Division of the New York Supreme Court, First Judicial Department Frank J. Aquila (1979), corporate lawyer, partner at Sullivan & Cromwell Umar Ata Bandial (1979), justice of the Supreme Court of Pakistan and former chief justice of Lahore High Court Lanny A. Breuer (1980), U.S. assistant attorney general for the Criminal Division Ronald Weich (1980), U.S. assistant attorney general for the Office of Legislative Affairs Paul Feinman (1981), judge of the New York Court of Appeals Michael H. Cohen (1983), healthcare law attorney, professor at Harvard Medical School Miguel Estrada (1983), controversial nominee to the United States Court of Appeals for the D.C. Circuit Steven Reich (1983), CEO of Deutsche Bank Trust Company and former associate deputy attorney general 2011–2013 Gary R. Brown (1985), judge of the United States District Court for the Eastern District of New York John H. Chun (1991), judge and nominee to the United States District Court for the Western District of Washington Andrew Ceresney (1993), chair of litigation practice at Debevoise & Plimpton and former head of enforcement at the U.S. Securities and Exchange Commission Veronica S.

=== Expansion === SHIELD Illinois was originally intended to be a facilitator, assisting laboratories in preparing to use the covidSHIELD assay and advising colleges, universities, and other organizations on how to collect specimens. SHIELD Illinois would also provide the technology needed to transmit orders to the lab and results back to the collecting agency. It was estimated that the program would have 50 testing locations and collect 1.5 million tests over a six-month period. Over time, SHIELD Illinois's role expanded beyond its original advisory function, and it became involved in the logistics of running both laboratories and collection sites. However, the estimated number of labs and locations remained the same. This changed in March 2021, when the University of Illinois System entered into an Intergovernmental Agreement with the Illinois Department of Public Health to offer testing to every school district, community college, and public university in Illinois, as well as community testing sites for the general public throughout the state. There are 853 school districts covering 3,977 with 1.9 million students in Illinois. As of October 2022, the company had performed over 6.5 million tests at over 1,700 sites in Illinois, including the governor's office, the state legislature, and the United States District Court for the Northern District of Illinois; engaged 12 CLIA or CAP-certified laboratories; and built a transportation network covering 80,000 square miles.

Sources: en.wikipedia.org

Frequently asked questions

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Is cardarine a steroid?

No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.

What do human studies show?

Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Network